[Neuronal dysfunction in multiple sclerosis]

Area of Science:

• Neuroscience
• Immunology
• Pathology

Background:

• Cortical damage mechanisms in multiple sclerosis (MS) are not fully understood.
• Microglia, the CNS resident immune cells, drive chronic neuroinflammation in MS cortical lesions.
• Microglia release neurotoxic factors including inflammatory cytokines (IFN-γ, IL-1β), reactive oxygen species (ROS), and glutamate.

Purpose of the Study:

• To elucidate the precise mechanisms of cortical damage in MS.
• To investigate the dual role of microglia in MS neuroinflammation and neuroprotection.
• To identify potential therapeutic targets for mitigating MS-related cortical damage.

Main Methods:

• Analysis of inflammatory mediators produced by microglia (e.g., IL-1β, ROS, glutamate).
• Investigation of neuronal signaling pathways involved in microglial activation (e.g., NLRP3, Th17 cells, gap junctions).
• Examination of neuroprotective factors released by damaged neurons (e.g., fractalkine, FGF-2) and their downstream effects.

Main Results:

• Microglial activation, induced by factors like NLRP3 and GM-CSF-producing Th17 cells, leads to the release of neurotoxic substances.
• Damaged neurons release fractalkine and FGF-2, which exert anti-inflammatory and anti-oxidant effects on microglia.
• Fractalkine promotes microglial debris clearance via MFG-E8, while FGF-2 enhances microglial migration through the FGFR3-Wnt-ERK pathway.

Conclusions:

• Microglia play a complex role in MS cortical lesions, contributing to both damage and potential repair.
• Neuronal-derived factors like fractalkine and FGF-2 offer a promising avenue for developing neuroprotective therapies in MS.
• Understanding these molecular interactions is crucial for future therapeutic strategies targeting cortical damage in MS.